Evidence map›Paper›PMID 35479514›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2022

Anticolon Cancer Targets and Molecular Mechanisms of Tao-He-Cheng-Qi Formula.

Zexin Zhang, Siqi Lin, Zifeng Liu, Jun Han, Jing Li, Yi Yu

Open access · hybridAbstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Zexin ZhangThe First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou 510405, China.ORCID https://orcid.org/0000-0002-2542-995X
Siqi LinThe Second Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou 510405, China.ORCID https://orcid.org/0000-0002-7405-6731
Zifeng LiuThe Second Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou 510405, China.ORCID https://orcid.org/0000-0003-4811-8799
Jun HanNational and Local Joint Engineering Research Center for Key Technology of Chinese Medicinal Composition Granules, Beijing Tcmages Pharmaceutical Co., Ltd., Beijing 101301, China.ORCID https://orcid.org/0000-0002-3634-3991
Jing LiThe First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha 410000, China.ORCID https://orcid.org/0000-0002-6547-1810
Yi YuThe First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha 410000, China.ORCID https://orcid.org/0000-0002-3996-4806
Guangzhou University of Chinese Medicine · CNFirst Affiliated Hospital of Hunan University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Tao-He-Cheng-Qi Formula (THCQF) is a traditional Chinese medicine that has been proven to have antitumor effects. The aim of this study was to elucidate the molecular targets and mechanisms of THCQF against colon cancer and construct a prognostic model based on network pharmacology, bioinformatics analysis, and in vitro experiments. Methods: Potential THCQF compounds and targets were retrieved from the Traditional Chinese Medicine Systems Pharmacology and Bioinformatics Analysis Tool for Molecular Mechanism of Traditional Chinese Medicine databases. Differentially expressed genes for colon cancer were screened in The Cancer Genome Atlas and Gene Expression Omnibus databases. The anticolon cancer mechanisms of THCQF were explored using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. Molecular docking simulations and molecular dynamics analysis were used to evaluate the binding between target proteins and active compounds. Finally, the identified compounds were used to treat colon cancer cells from the HCT116 cell line, and expression of mRNA and protein after relevant posttreatment were tested using real-time polymerase chain reaction and western blotting. Results: A total of 27 anticolon cancer targets of THCQF were selected, among which four genes ( Conclusions: Taken together, the results indicate that AE and QR are the pivotal active compounds of THCQF, and

Identifiers

PMID35479514
PMCPMC9038428
OpenAlexW4224235539

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.